Sortina Pharma AB announces official publication of the issued Swedish patent no. 2151469-0

Sortina Pharma AB announces official publication of the issued Swedish patent no. 2151469-0

Sortina Pharma, an oncology focused startup founded in 2020 based on research originating from Gothenburg University, today announces the official publication of the issued Swedish patent no. 2151469-0, which relates to novel sortilin binding molecules inhibiting the binding of effector molecules to sortilin.

Sortina Pharma anticipates favorable outcomes in other countries as well, given the positive search reports from the Swedish and European Patent Offices.

This first patent will provide Sortina Pharma with protection for a group of small molecules binding to sortilin. Several cancer types have subgroups of patients with increased expression of sortilin, all signifying a patient population with highly aggressive cancer, less responsive to treatment and with lower chance of survival.

“To specifically target a subgroup of cancer cells involved in cancer spread and metastases via the novel anti-sortilin binding molecules will represent a significant contribution to future optimized cancer treatment strategies” says one of the founders of Sortina Pharma, Professor Göran Landberg. “We look forward to further develop this exceptional cancer treatment opportunity.”

Sortina Pharma has reached several milestones in developing first in class novel anti-sortilin binding small molecules for the treatment of aggressive cancer and the molecules show great results in pre-clinical testing using model systems for aggressive cancer as well as patient derived material.

We are very satisfied with the protection of our highly potent sortilin binding molecules which leads to the ability to advance the development of a novel treatment option for the most aggressive and non-treatable cancers, one of the toughest medical challenges we face today, says Sara Rhost, CEO of Sortina Pharma.

The development of first in class anti-sortilin products provides a great opportunity in advancing cancer treatment towards curing more patients. The issuing of this patent is an important milestone for Sortina, says Sara Malcus, Chairman of the Board, Sortina Pharma.

For more information, please contact

Sara Rhost, CEO, sararhost@sortinapharma.com